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Excision of the infected aortic prosthesis and
extra-anatomic bypass grafting through a noninfect-
ed field has been the most common treatment for
patients with aortic graft infection. Results of the use
of this approach have gradually improved since its
introduction by Blaisdell et al in 1970,1 particularly
after the observation of Reilly et al2 that staged
extra-anatomic bypass grafting followed by graft
excision was associated with lower mortality and
improved initial limb salvage. However, in their
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Objective: The purpose of this study was to determine long-term outcome in patients
with infected prosthetic aortic grafts who were treated with extra-anatomic bypass graft-
ing and aortic graft removal. 
Methods: Between January 1989 and July 1999, 36 patients were treated for aortic graft
infection with extra-anatomic bypass grafting and aortic graft removal. Extra-anatomic
bypass graft types were axillofemoral femoral (5), axillofemoral (26; bilateral in 20),
axillopopliteal (3; bilateral in 1) and axillofemoral/axillopopliteal (2). The mean follow-
up was 32.3 ± 4.8 months.
Results: Four patients (11%) died in the postoperative period, and two patients died dur-
ing follow-up as a direct consequence of extra-anatomic bypass grafting and aortic graft
removal (one died 7 months after extra-anatomic bypass graft failure, one died 36
months after aortic stump disruption). One additional patient died 72 months after fail-
ure of a subsequent aortic reconstruction, so that the overall treatment-related mortali-
ty was 19%, whereas overall survival by means of life table analysis was 56% at 5 years.
No amputations were required in the postoperative period, but four patients (11%)
required amputation during follow-up. Twelve patients (35%) had extra-anatomic
bypass graft failure during follow-up, and six patients underwent secondary aortic
reconstruction (thoracobifemoral [2], iliofemoral [2], femorofemoral [2]). However,
with the exclusion of patients undergoing axillopopliteal grafts (primary patency 0% at
7 months), only seven patients (25%) had extra-anatomic bypass graft failure, and only
two patients required amputation (one after extra-anatomic bypass graft removal for
infection, one after failure of a secondary aortic reconstruction). Furthermore, primary
and secondary patency rates by means of life table analysis were 75% and 100% at 41
months for axillofemoral femoral grafts and 64% and 100% at 60 months for
axillofemoral grafts. Only one patient required extra-anatomic bypass graft removal for
recurrent infection, and only one late aortic stump disruption occurred.
Conclusions: Staged extra-anatomic bypass grafting (with axillofemoral bypass graft) and
aortic graft removal for treatment of aortic graft infection are associated with acceptable
early and long-term outcomes and should remain a primary approach in selected patients
with this grave problem. (J Vasc Surg 2000;32:451-61.) 
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review of the surgical treatment of prosthetic graft
infection between 1980 and 1992, Yeager and
Porter3 reported that this type of treatment was
associated with an average mortality rate of 21%, an
average amputation rate of 11%, and an average
recurrent infection rate of 18%. Furthermore, long-
term patency rates for axillofemoral bypass grafts
done for revascularization in patients with infected
aortic grafts have generally been low (43% primary
patency at 3 years).4 These relatively poor results,
particularly the risks of long-term graft occlusion
and recurrent infection, have led to the investigation
of newer methods of treating prosthetic aortic graft
infection including in situ replacement of the infect-
ed aortic graft with a new prosthetic graft, a homo-
graft, or a graft constructed of superficial femoral
vein.5-9
Long-term patency of axillofemoral femoral
bypass grafts used for the treatment of aortoiliac
occlusive disease and for revascularization during
treatment of aortic sepsis has recently been reported
to be improved by the use of externally supported
prosthetic grafts. Taylor et al10 reported a 71% pri-
mary and a 79% secondary graft patency at 5 years in
164 patients undergoing axillofemoral femoral
bypass grafts done primarily for ischemia due to aor-
toiliac disease. Similarly, Yeager et al11 (from the
same institution) reported a 73% primary and 92%
secondary patency at 5 years in 60 patients under-
going axillofemoral grafts for revascularization dur-
ing treatment of both aortic graft infection and pri-
mary aortic sepsis. Yeager et al11 also demonstrated
late aortic stump disruption, previously a common
cause of late death after infected aortic graft removal
and extra-anatomic bypass grafting,12 to now be
uncommon. Thus, results after “conventional” man-
agement of aortic graft infection with staged extra-
anatomic bypass grafting followed by graft excision
may not be as disappointing as previously thought.
This study was designed to further evaluate initial
and long-term results after treatment of patients
with aortic graft infection with staged extra-anatom-
ic bypass grafting and aortic graft removal.
MATERIALS AND METHODS
Patients. Thirty-six patients treated for aortic
graft infection with staged extra-anatomic bypass
grafting and excision of the infected aortic graft
between January 1989 and July 1999 were identified
from a prospectively collected computerized vascular
database (of 64 patients with thoracic, suprarenal,
and infrarenal aortic graft infection, including those
with actively bleeding aortoenteric fistulas treated
during that time period). Patients with actively bleed-
ing aortoenteric fistulas and infected thoracic and
suprarenal aortic grafts and those treated with aortic
graft excision (partial or complete) alone were
excluded from this review. All patients reviewed were
thought to require arterial reconstruction before aor-
tic graft removal because of placement of the infect-
ed aortic graft for aneurysmal disease or for severe
limb ischemia. Attempted graft preservation was not
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Fig 1. Kaplan-Meier cumulative survival plot of patient survival after treatment of aortic graft infec-
tion. Survival SEs are less than 10% through 60 months.
done in any of these patients on the basis of the sur-
geon’s preference and poor previous experience with
this approach in this institution. Complete medical
records including follow-up records were reviewed,
and demographics and initial and long-term out-
comes were determined. The mean age of the
patients at the time of treatment of the aortic graft
infection was 61.8 ± 2.3 years, and 27 patients (75%)
were men. The original indication for the aortic
reconstruction was infrarenal aortic aneurysm in 12
patients, aortoiliac occlusive disease in 22 patients,
and both aneurysmal and occlusive disease in 2
patients. Configurations of the infected aortic grafts
were aortobifemoral in 32 patients, aortobi-iliac in 2
patients, and aorta-aortic in 2 patients.
The initial presenting sign of the aortic graft infec-
tion was groin sepsis in 16 patients, systemic sepsis in
11 patients, anastomotic pseudoaneurysm in 5
patients, and lower limb ischemia in 4 patients. The
mean time between aortic graft implantation and pre-
sentation with aortic graft infection was 56.5 ± 9.5
months. A presumed diagnosis of aortic graft infec-
tion was made with computed tomographic findings
of perigraft fluid, perigraft inflammation, perigraft
abscess, multiple anastomotic pseudoaneurysms, and
graft cutaneous fistula in 32 patients, whereas four
patients presented with exposed graft in an open,
infected groin wound. Perigraft purulence and lack of
graft incorporation at surgical exploration confirmed
the presumed diagnosis of graft infection in all
patients. Infection involved the entire aortic graft in
28 patients and was confined to a portion of one limb
of an aortobifemoral bypass graft in the remaining
eight patients.
Surgical treatment and postoperative care.
Preliminary extra-anatomic bypass grafts were per-
formed as separate procedures before complete or
partial removal of the infected aortic graft in all
patients. All extra-anatomic bypass grafts originated
from the first portion of the axillary artery and were
done with externally supported 8-mm polytetrafluo-
roethylene grafts. The distal anastomoses were done
to the common femoral artery when the groin was
uninvolved with infection, and an axillofemoral
femoral configuration with the axillofemoral limb
tunneled medial to the anterior superior iliac spine
was used whenever possible. When groin sepsis was
present, the distal anastomosis was done to the
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Fig 2. Kaplan-Meier cumulative survival plot of primary and secondary patency per patient of axil-
lopopliteal bypass grafts. Survival SEs are more than 10% at all time points.
Configuration of extra-anatomic bypass grafts used for
revascularization in patients with aortic graft infection
Patients 
Axillofemoral femoral 5
Bilateral axillofemoral 20
Unilateral axillofemoral 6
Bilateral axillopopliteal 1
Unilateral axillopopliteal 2
Axillofemoral/axillopopliteal 2
mid–profunda femoris artery, the proximal superfi-
cial femoral artery, or the above-knee popliteal
artery, and unilateral bypass grafts were routed later-
al to the anterior superior iliac spine through clean
tissue planes. The mid–profunda femoris and proxi-
mal superficial femoral arteries were approached
through an incision lateral to the sartorius muscle,
whereas the above-knee popliteal artery was
approached through the tensa fascia lata. The extra-
anatomic bypass grafts were tunneled subfascially
from the femoral or popliteal incisions to the axillary
incisions beneath the pectoralis major and minor
muscles and parallel to the axillary artery for a dis-
tance of approximately 5 cm. Axillopopliteal bypass
grafts were only used early in this series and were
abandoned when their high failure rate became
obvious. Configurations of the extra-anatomic grafts
in the 36 patients treated for aortic graft infection
are shown in the Table. Six to 12 hours after com-
pletion of the extra-anatomic bypass graft proce-
dures, patients were anticoagulated with intravenous
heparin until the subsequent procedure for aortic
graft removal was performed. This was done to
potentially protect against extra-anatomic graft
thrombosis due to competitive flow and was insti-
tuted after thrombosis of two extra-anatomic bypass
grafts occurred during the interval before aortic
graft removal before the time frame of this study.
Intravenous antibiotics were also continued until the
subsequent graft removal procedure.
Removal of the infected aortic graft was done at
a mean of 3.9 ± 2.4 days after the extra-anatomic
bypass grafting procedures. The interval between the
staged procedures was based on the patient’s condi-
tion after the extra-anatomic bypass grafting proce-
dure, the urgency of aortic graft removal, and the
availability of operating room time. An ideal interval
of 2 to 3 days was sought. Patency of the extra-
anatomic bypass grafts in the patients treated for 
aortobifemoral graft infection was confirmed before
the aortic graft excision was begun by the continuing
presence of a continuous wave Doppler scan signal in
the pedal vessels with digital compression of the
femoral graft limbs. One femoral-femoral graft and
one axilloprofunda femoris graft were found to be
occluded by this maneuver, and patency of these
grafts was restored by thrombectomy before begin-
ning the aortic graft removal procedure. These two
patients had not been anticoagulated between the
initial extra-anatomic bypass graft procedure and the
graft removal procedure. The infected aortic grafts
were removed in their entirety with the use of a trans-
abdominal approach, and the infrarenal aortic stump
was debrided and closed with at least two layers of
monofilament suture. Insufficient length of nonin-
fected, infrarenal aortic tissue for secure closure after
debridement was encountered in one patient, and
extra-anatomic hepatorenal and splenorenal bypass
grafts were performed to allow suprarenal aortic clo-
sure. Bowel defects were repaired when encountered
JOURNAL OF VASCULAR SURGERY
454 Seeger et al September 2000
Fig 3. Kaplan-Meier cumulative survival plot of primary and secondary patency per patient of
axillofemoral bypass grafts. Survival SEs are more than 10% after 43 months.
(jejunum [1], sigmoid colon [2], indication for orig-
inal aortic graft: aneurysm [1], occlusive disease [2])
with lateral closure or resection. The retroperitoneal
wound was debrided, cultured, and drained as appro-
priate (suction drains brought out through separate
incisions were placed when obvious abscess cavities
were encountered). In patients with aortofemoral
graft infections, graft limbs were first disconnected
from the femoral arteries, which were closed with
vein patch angioplasties, followed by transabdominal
removal of the remainder of the graft. In patients
with an infection confined to the groin portion of
one limb of an aortofemoral graft limb, the affected
graft limb was first divided at a well-incorporated
portion of the graft in the pelvis and approached
through a lower quadrant retroperitoneal incision.
The limb stump was then cultured, and the limb
pseudocapsule closed over this stump, followed by
closure and sterile exclusion of the retroperitoneal
incision. The infected groin was then opened, the
divided graft limb was detached from the femoral
artery and removed through the groin wound, and
the femoral artery was closed with a vein patch angio-
plasty.
Intravenous antibiotics were administered for at
least 2 weeks after infected graft removal followed by
culture-specific oral antibiotics until all systemic evi-
dence of sepsis had resolved for at least 6 additional
weeks after hospital discharge. Antibiotic selection
was based on culture results from the time of graft
removal, if positive, or from the most recent 
positive culture during the preoperative period.
Continuation of antibiotics for 6 weeks and termi-
nation at this point were arbitrary and were not
based on the type of organism cultured. Patients
were routinely treated with aspirin, 325 mg/d, and
23 patients (64%) also underwent long-term antico-
agulation with warfarin at the discretion of the
attending surgeon. After wound healing, patients
were evaluated every 3 months during the first year
of follow-up and every 6 months thereafter. Extra-
anatomic bypass graft patency was assessed at the
time of follow-up by means of clinical examination,
duplex graft scanning, and measurement of
ankle/brachial systolic pressure indices. Early in the
series, patients underwent thrombectomy or
catheter-directed thrombolysis for graft occlusion,
whereas later occluded grafts were generally replaced
with a new extra-anatomic or aortic graft (if the
patient had been free of infection for at least 12
months).
Analysis. Primary graft patency was terminated
at the initial episode of extra-anatomic bypass graft
failure (thrombosis or infection). Secondary patency
was calculated as a composite patency and included
patency after thrombectomy/thrombolysis and after
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Fig 4. Kaplan-Meier cumulative survival plot of primary and secondary patency per patient of
axillofemoral femoral bypass grafts. Survival SEs are more than 10% at all time points.
graft revision/replacement as previously described
by Yeager et al.11 Long-term primary and secondary
graft patency, limb salvage, and survival were deter-
mined with the Kaplan-Meier life table methods. A
log-rank test was used to compare life table curves.
χ2 Analysis was used to identify possible predictors
of graft patency and limb salvage. Follow-up for
graft patency and limb salvage was complete in 28
patients and partial in seven patients, whereas one
patient was lost to follow-up shortly after hospital
discharge. Survival information was available in all
patients. The mean follow-up was 32.3 ± 4.8
months.
RESULTS
Fifteen patients (41.7%) had significant postop-
erative complications including respiratory failure
requiring prolonged ventilation in 6 patients,
myocardial infarction in 5 patients, renal failure
requiring dialysis in 4 patients, wound hematomas
requiring evacuation in 3 patients, sepsis in 3
patients, and limb ischemia in 2 patients (due to
extra-anatomic graft thrombosis in 1 patient). No
amputations were required during the postoperative
period, and all complications occurred after the aor-
tic graft removal procedure. Four patients (11%)
died postoperatively, three of multiple organ dys-
function due to sepsis and one after a myocardial
infarction. Two additional patients died during 
follow-up as a direct consequence of their aortic
graft infection treatment, one at 7 months after
thrombectomy for axillopopliteal bypass graft
thrombosis and one at 36 months after aortic stump
disruption. Another patient died 72 months after
failure of a subsequent thoracobifemoral bypass graft
performed for recurrent axillofemoral bypass graft
failure. Thus, mortality directly related to the treat-
ment of aortic graft infection (postoperative and
during follow-up) with extra-anatomic bypass graft-
ing and aortic graft excision was 16.7%, and overall
treatment-related mortality was 19.4%. Thirteen
additional patients died of causes unrelated to the
treatment of their aortic graft infection during 
follow-up. Survival by means of life table analysis
was 73% at 3 years and 56% at 5 years (Fig 1).
Twelve patients (35.3%) who survived the post-
operative period and participated in long-term 
follow-up had extra-anatomic bypass graft failure
during follow-up (11 due to graft thrombosis and
one due to graft infection). Three patients undergo-
ing axillofemoral bypass grafting and one patient
undergoing axillofemoral femoral bypass grafting
died during the postoperative period, and one
patient undergoing axillofemoral bypass grafting was
lost to follow-up. All five patients (100%) undergo-
ing axillopopliteal bypass grafting had graft failure
due to graft thrombosis. Four had multiple episodes
of axillopopliteal graft thrombosis and two subse-
quently had new grafts placed in a new location (one
iliofemoral bypass graft and one femorofemoral
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Fig 5. Kaplan-Meier cumulative survival plot of limb salvage in all patients undergoing treatment of
aortic graft infection. Survival SEs are more than 10% after 54 months.
bypass graft), one underwent an amputation, and
one died after undergoing a graft thrombectomy.
The remaining patient with axillopopliteal graft fail-
ure had only claudication after his initial episode of
graft thrombosis and did not undergo treatment of
the occluded graft. Two patients undergoing unilat-
eral axillopopliteal bypass grafting had an
axillofemoral bypass graft on the contralateral side,
and these grafts remained patent throughout follow-
up. Primary patency of axillopopliteal bypass grafts
was 0% at 7 months, whereas secondary patency was
53% at 17 months and 27% by 50 months (Fig 2).
However, because of the small number of patients
undergoing axillopopliteal bypass grafts, life table
survival SEs exceeded 10% at all time points. 
Six (25%) of 24 patients undergoing axillofemoral
bypass grafts who participated in long-term follow-
up had bypass graft failure (five due to graft throm-
bosis and one due to infection). One patient had
infection of bilateral axillofemoral bypass grafts and
underwent graft excision and amputation, when
infection was found in one axillofemoral graft, and
underwent graft excision and new iliofemoral bypass
graft when the contralateral extra-anatomic bypass
was demonstrated to be infected. This problem was
managed at another institution, and no attempt was
made to salvage these infected extra-anatomic bypass
grafts. The infection did appear to be due to the same
organism that was responsible for the original aortic
graft infection. A second patient had two episodes of
axillofemoral bypass graft thrombosis after which he
underwent a thoracobifemoral bypass graft. The
remaining four patients only had a single episode of
axillofemoral graft failure, and two of these patients
were treated with thrombectomy/thrombolysis
alone, one underwent a thoracobifemoral bypass
graft, and one underwent a femorofemoral bypass
graft. Primary patency of axillofemoral grafts was
85.6% at 1 year, 80% at 3 years, and 64% at 5 years,
and secondary patency was 100% at all of those time
points (Fig 3). One (25%) of four patients undergo-
ing axillofemoral femoral bypass graft who participat-
ed in long-term follow-up had a single episode of
graft thrombosis, and this was treated with graft
thrombectomy. Primary patency of axillofemoral
femoral bypass grafts was 75%, and secondary paten-
cy was 100% at 41 months (Fig 4). Again, because of
the small number of patients in this group, survival
SEs were more than 10% at all time points.
Primary and secondary patencies of axillofemoral
and axillofemoral femoral grafts were significantly
greater than the patency of axillopopliteal grafts (P <
.001). Furthermore, freedom from graft failure by
means of life table analysis in patients treated for aortic
graft infection with axillofemoral or axillofemoral
femoral bypass grafting and aortic graft excision who
survived the postoperative period and who participat-
ed in long-term follow-up was 84% at 1 year, 79% at 3
years, and 63% at 5 years. Examination of potential
predictors of graft failure, including long-term antico-
agulation, infected aortic bypass graft configuration,
indication for the original aortic reconstructive proce-
dure, and extra-anatomic bypass graft configuration,
revealed only the use of axillopopliteal bypass grafting
to be associated with bypass graft failure (P < .01, χ2
analysis). 
Four patients (11%) required five amputations
during follow-up. Amputation was done after
axillofemoral graft removal for infection in one
patient, after multiple failures of an axillopopliteal
bypass graft in one patient, and after failure of subse-
quent aortoiliac reconstructive procedures in two
patients (thoracobifemoral bypass graft in one requir-
ing bilateral amputations, iliofemoral bypass graft in
one). The amputations necessitated by failure of the
original extra-anatomic bypass grafts were done at 15
and 17 months of follow-up, whereas those associat-
ed with failure of subsequent aortoiliac reconstruc-
tive procedures were done at 56, 60, and 72 months
after treatment of the aortic graft infection. Two of
the patients who required amputation had under-
gone axillopopliteal bypass grafting, and two had
undergone axillofemoral bypass grafting. No ampu-
tations were required in the patients who underwent
axillofemoral femoral bypass grafting. Limb salvage
in patients undergoing axillofemoral grafting was
100%, 97%, and 97% at 1, 3, and 5 years, respective-
ly, whereas limb salvage in patients undergoing axil-
lopopliteal bypass grafting was 100% at 7 months,
75% at 17 months, and 50% at 5 years. Again, sur-
vival SEs were more than 10% at all time points in the
axillopopliteal group. Limb salvage for all patients in
the study was 100% at 1 year, 92% at 3 years, and
80.5% at 5 years (Fig 5). No predictors of limb sal-
vage were identified with univariant analysis.
Recurrent infection in an extra-anatomic bypass
graft occurred in only the one previously described
patient with bilateral axillofemoral bypass graft infec-
tion. Late aortic stump disruption also occurred only
in the patient with juxtarenal aortic infection who had
required extra-anatomic renal artery bypass grafting
to allow debridement and aortic stump closure. Only
two patients underwent subsequent infrainguinal
bypass grafting during follow-up, despite the indica-
tion for the original aortic reconstruction being aor-
toiliac arterial occlusive disease in 75%.
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DISCUSSION
Our results of treatment of infected aortic pros-
thetic grafts with staged extra-anatomic bypass graft-
ing and aortic graft excision are significantly better
than the average results found by Yeager and Porter3
in their 1992 review. Postoperative mortality was
11%, the amputation rate was 11%, 5-year primary
and secondary graft patency rates were 64% and
100% (in patients undergoing axillofemoral and
axillofemoral femoral bypass grafting), and the 5-
year limb salvage rate was 82%. In contrast, patency
rates for axillopopliteal bypass grafts were unaccept-
able, which confirmed results from a previous review
of our experience with treatment of aortic graft
infection,13 and the use of axillopopliteal bypass
grafts was abandoned early in this series. Admittedly,
the overall number of patients reviewed in this study
and the numbers of patients in the subgroups are
small, which introduces the potential for bias.
However, with the exclusion of the patients under-
going axillopopliteal bypass grafting, the results
reported here are strikingly similar to those recently
reported by Yeager et al in 1998,11 with a similar
conventional approach in the management of
patients with aortic sepsis (operative mortality 13%,
amputation rate 10%, and 5-year limb salvage rate
82%). The patency rates of our axillofemoral bypass
grafts are also very similar to the patency rates of the
axillofemoral femoral bypass grafts used by Yeager et
al11 (primary patency 73%, composite secondary
patency 92% at 5 years), and, like those authors, we
found extra-anatomic graft infection and aortic
stump disruption to be uncommon. 
Aortic graft infection can also be treated with
simultaneous aortic graft excision and in situ aortic
graft replacement with a variety of new aortic grafts
(an autogenous graft, a homograft or a new pros-
thetic graft). Clagett et al8 and Nevelsteen et al9 have
reviewed the use of autogenous grafts constructed
from deep femoral veins to treat 41 and 15 patients
with infected aortic grafts. Postoperative mortality
rates were 10% and 7%, respectively, in these studies,
and early amputation rates were 5% and 7%.
Furthermore, Clagett et al8 reported that primary
and secondary graft patency rates at 5 years were 83%
and 100%, 5-year limb salvage was 86%, and signifi-
cant lower extremity edema was uncommon.
However, the mean operative time for in situ aortic
graft replacement with a graft constructed of superfi-
cial femoral vein in Clagett’s study was 7.9 hours,
and major postoperative morbidity occurred in 49%
of the patients, including compartment syndrome in
12% and limb paralysis in 7.5%. Kieffer et al7 used
aortic allografts to replace infected prosthetic aortic
grafts in 43 patients, including 36 with infrarenal aor-
tic graft infections, with a postoperative mortality of
12% and no early amputations. However, allograft
complications occurred in 11 patients (26%) includ-
ing one allograft graft rupture, one graft thrombosis,
one graft enteric fistula, and one late death possibly
due to persistent or recurrent infection. Hayes et al5
used rifampicin-bonded polyester grafts to replace
infected prosthetic aortic grafts in 11 patients with a
postoperative mortality of 18.2% and no early ampu-
tations. Unfortunately, significant graft-related com-
plications were also common in this series with two
patients dying of recurrent graft infections within 30
months. Finally, Towne et al6 treated 14 patients who
had prosthetic aortic graft infection due to
Staphylococcus species biofilms with graft excision and
in situ graft replacement with a new prosthetic graft.
There were no initial mortality or limb loss and no
late graft failure at an average follow-up of 3 years.
However, all of the patients in Towne et al’s study
had limited infections so that only a portion of the
aortic graft was replaced, and two patients had evi-
dence of infection of the remainder of the aortic graft
during follow-up.
The outcomes after treatment of aortic graft
infection with extra-anatomic bypass grafting and
graft excision and in situ autogenous graft replace-
ment are acceptable and appear comparable. In con-
trast, the catastrophic complications associated with
allograft and antibiotic-bonded graft in situ replace-
ment appear to limit the usefulness of these
approaches in all but a very few patients in whom no
other options are available. Long-term graft failure
after extra-anatomic bypass graft and graft excision
appears higher than after in situ graft replacement
with a graft made from the superficial femoral vein.
However, simultaneous graft removal and in situ
graft replacement with an autogenous graft is a
demanding procedure for the patient (and the sur-
geon), and the study by Reilly et al14 documented
that staged graft removal and revascularization pro-
cedures limit physiologic stress compared with
simultaneous procedures. Furthermore, although
operative mortality associated with in situ replace-
ment of the infected aortic graft with an autogenous
graft and staged extra-anatomic bypass grafting and
infected graft excision are equivalent, postoperative
complications associated with in situ autogenous
graft replacement, particularly limb paralysis and
compartment syndrome, appear more serious.
Regardless, both approaches appear to have roles in
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the management of patients with aortic graft infec-
tion. In situ autogenous graft replacement may be
most appropriate in younger, healthier patients who
have a greater life expectancy and, thus, a higher risk
of long-term graft failure, whereas staged extra-
anatomic bypass grafting and graft excision may be
better in older, sicker patients in whom long-term
graft failure may be less important. In addition,
extra-anatomic bypass graft is not feasible in patients
with severe profunda femoris and proximal superfi-
cial femoral arterial occlusive disease.
Despite these improved modern results, prosthet-
ic aortic graft infection remains a grave problem.
Mortality associated with the treatment of aortic
graft infection remains at least 10%, which reflects the
magnitude of the procedures necessary to treat this
complex problem and the inability, at times, to con-
trol aortic and retroperitoneal sepsis despite removal
of the infected prosthesis. In addition, the amputa-
tion rate associated with the treatment of an infected
aortic prosthesis is up to 10%, particularly when an
infected aortobifemoral graft is treated. This is not
surprising because the infected aortic graft is in the
most favorable anatomic position for revasculariza-
tion and patients with infected aortobifemoral bypass
grafts usually have significant infrainguinal arterial
occlusive disease, which makes maintenance of ade-
quate lower extremity perfusion after graft removal
difficult. Yeager et al11 found extra-anatomic bypass
graft failure to be more common in patients treated
for infected aortobifemoral grafts originally placed
for occlusive disease, and we have also previously
demonstrated long-term limb salvage to be lowest in
patients whose infected aortic grafts were placed for
the treatment of occlusive disease.13 Furthermore,
although the use of externally supported grafts
appears to have improved long-term patency of
extra-anatomic bypass grafts, long-term graft failure
still occurs in 25% to 35% of patients after extra-
anatomic bypass grafting and infected aortic graft
excision; adjuncts such as long-term anticoagulation
do not appear to reduce this failure rate. Therefore,
extra-anatomic bypass graft revision/replacement
procedures must be done in a significant number of
patients to achieve the good long-term limb salvage
rates seen here and reported by Yeager et al.11
We have confirmed that modern results of staged
extra-anatomic bypass grafting followed by infected
aortic graft excision justify continued use of this rel-
atively straightforward treatment in patients with
prosthetic aortic graft infection. However, the man-
agement of patients with infected prosthetic aortic
grafts remains challenging. Familiarity with multiple
treatments, experience with complex surgical recon-
structions, and careful long-term follow-up are nec-
essary to achieve optimal results. 
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Dr G. Patrick Clagett (Dallas, Tex). I applaud the
authors in presenting an honest and realistic appraisal of
extra-anatomic bypass for this grave condition. The results
are about as good as one can expect, but they are not
good. A mortality due to treatment of 19%, with 35% suf-
fering extra-anatomic bypass failure from thrombosis
and/or infection, and an 11% amputation rate leads me to
conclude that this is not optimal treatment. We need to do
better, and I strongly disagree with your conclusion that 
“. . . this should remain a primary approach . . .” and that
the results “. . . justify its continued use.”
I would conclude the opposite. In our series using the
superficial femoropopliteal vein as an in situ replacement,
the mortality from treatment is less than 10% and even
lower if we exclude patients with actively bleeding aortoen-
teric fistulas. Patency is simply not an issue, even in patients
with severe multilevel occlusive disease. The only late ampu-
tations that we have performed have been for progressive
distal occlusive disease, and the proximal autogenous deep
vein reconstructions have remained patent. In addition, our
morbidity from the procedure is really not much different
from yours and, I suspect, is more related to patient-
specific comorbidities and not to procedure-related differ-
ences. Furthermore, our patients require only perioperative
antibiotics and are not treated with long-term warfarin.
Since we have become a repository for infected grafts in
the great state of Texas, we are increasingly referred patients
who have infected and failing extra-anatomic bypass. They
have already had their infected aortic grafts removed and
have extra-anatomic bypass with its secondary complica-
tions. These are the toughest, sickest patients, and even our
procedure is not so hot in this group. We call these “ter-
tiary” procedures because they are usually the third, or
more, major operation for graft infection, and another
extra-anatomic bypass is simply not possible. Because of
this, we feel that the deep vein reconstruction is optimal as
the first procedure for aortic graft infection and that extra-
anatomic bypass should be used less.
Having said this, I would agree entirely that one can-
not be wed to one single operation in the treatment of
these complex patients. For patients with infected aortoil-
iac bypasses, groins that are free of sepsis, and good
runoff, extra-anatomic bypass is an excellent choice, and I
use it. Unfortunately, these patients are uncommon in our
experience. Most have infected aortofemoral bypasses,
“pussed-out” groins, and severe occlusive disease. For
these, extra-anatomic bypass remains a compromised
operation for a compromised patient. 
A few questions. First, in what type of patients do you
recommend long-term warfarin with or without aspirin,
and have you seen bleeding complications? Two, is paten-
cy adversely affected when the profunda femoris artery is
the only patent outflow? And three, what do you recom-
mend for patients with diseased, small profunda arteries
and occluded superficial femoropopliteal arteries?
I enjoyed this paper and once again congratulate the
authors for confirming my biases. Thank you.
Dr James M. Seeger. Thank you, Pat. To first address a
couple of points you raised and then to answer your ques-
tions. 
The 19% mortality is of course worst case scenario,
and I think it is important to recognize that the two late
deaths that occurred after subsequent aortic reconstruc-
tions occurred after 5 years of follow-up, so they certainly
are related in some manner to the overall treatment of aor-
tic graft infection. That is clearly giving you the worse case
scenario about mortality.
The 11% amputation rate, similar to what you have
seen, occurred in those patients who underwent subse-
quent infrainguinal bypass reconstructions. We did have
some failure of the proximal reconstructions, but they
failed when the recurrent distal reconstructions had failed. 
To answer your specific questions. In which patients
do we use Coumadin? I am not sure when to use
Coumadin in these patients. One of the things that we had
hoped to find from this analysis was to show that
Coumadin would be of value. Only about 60% of patients
in this study actually were treated with long-term antico-
agulation, but that was not a predictor of graft failure. 
Have we seen bleeding complications? We actually
have not. I have been surprised both in this study and in
the study of the lower extremity bypass patients in which
we now use Coumadin fairly commonly that we have seen
very few long-term bleeding complications in these
patients. That may be related to the fact that our nurse,
Laurie Carlton, spends so much time making sure that
these people’s INRs stay within the proper level, but I
think it does show that even with these patients with rela-
tively significant disease they can be carefully managed
with their Coumadin without risk.
Is the patency adversely affected by profunda femoris
artery disease? It does not appear to be. However, I must
admit we are selective in which patients we use axillopro-
funda femoris bypass and this leads into your third ques-
tion. What do we do in patients with occluded superficial
femoral arteries and diseased profunda femoris arteries? In
those patients who have poor profunda femoris arteries as
their only outflow, we do not use extra-anatomic bypass-
es. We use the same operation that you use, constructing
a new graft out of deep vein. 
It has been our overall clinical impression, although
we do not have as large a series as you have, that this oper-
ation is a bit more physiologically strenuous for elderly
people. Therefore, what we are doing at this point in time
is, as you say, using both operations selectively for various
patients and in the patients who are young and healthy,
and we would expect to have a good long-term survival.
We will consider replacing them with a neoaorta, whereas
in the elderly and ill patients we use staged extra-anatom-
ic bypass and graft excision. The thing that is disappoint-
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ing is that the postoperative mortality appears somewhat
unpreventable, because at least in our series, it was essen-
tially related to multiorgan dysfunction and an inability to
control the septic process. It may well be that we got these
patients late, but even with taking the graft out and
debriding the retroperitoneum we still had that problem. 
Dr G. Melville Williams (Baltimore, Md). I have treated
seven patients with aortic graft infection using fresh aortic
allografts and all of these patients have done well. One in par-
ticular was septic at the time with a Staphylococcus aureus
abscess and aortic aneurysm rupture at the time he was
replaced above the renal arteries. There was really no other
option in this particular patient, and he has been free of any
dilatation or deleterious effects of the allograft for 7 years.
The only dilatations we have had using fresh allografts have
been in the infra-aortic segments. One patient had an aorto-
bipopliteal allograft, and degeneration of the infra-aortic seg-
ments occurred and had to be ligated. The aortic portion was
oversewn. Our cardiac surgery colleagues use cryopreserved
aortic allografts with impunity in operating on patients with
prosthetic graft infections without any evidence whatsoever of
deleterious long-term effects. I have recently put in a cryo-
preserved descending thoracic aortic graft to replace the
abdominal aorta in a patient with a disk abscess and a psoas
abscess busting into the aorta. Short term, he is okay. I can
tell you over an 8-year experience with seven fresh allografts
that no problem has occurred, and we wonder if we are not
forgetting the fact that cryopreserved grafts might very well
perform a very useful function in these patients once the
majority of the sepsis is under control with antibiotics. I raise
this as an additional possibility because you achieve every-
thing you require with a much easier operation than trying to
take out the confounded superficial femoral veins. 
Dr Seeger. Thank you, Mel. You are right that our car-
diac colleagues tend to use cryopreserved allografts fairly
commonly in this situation. Our experience with this kind
of thing has been limited to those people who have tho-
racic or particularly suprarenal infections. The only con-
cern that I raise with that is Keifer’s study, which is the
largest that I am aware of using homograft replacement of
infected aortic grafts, and he reported an almost 30% 
allograft-related complication rate including a couple of
late deaths due to allograft blowout.
Thank you.
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